On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.
Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."
Data provided by Nasdaq. Minimum 15 minutes delayed.
June 21, 2017
Nuvectra Files Regulatory Submission with FDA for Algovita® MRI-Conditional Approval
PLANO, Texas, June 21, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has filed its regulatory submission with the U.S. Food and Drug Administration (FDA) for full-body MRI-conditional approval for the Company’s Algovita SCS system. Scott Drees, Chief Executive Officer, commented, “This submission to the FDA represents our continued commitment to the advancement of the Algovita system. The addition of a full bo
May 09, 2017
Nuvectra™ Reports First Quarter 2017 Financial Results
PLANO, Texas, May 09, 2017 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today financial results for the first quarter ended March 31, 2017. Highlights Record total revenues of $5.0 million, including total Algovita sales of $3.4 million U.S. commercial team building momentum with new and existing customers Remain on track with the Virtis U.S. and European regulatory approval timelines Scott Drees, CEO, said, “We c
The Ruth Group
|There are currently no events scheduled.|